GLP-3

What is the GLP-3 peptide?

GLP-3 is a name in wide circulation, and the research behind this page contains no molecule that carries it. No source among the research behind this page describes a compound called GLP-3. What is absent is not a finding about GLP-3; it is the molecule that any such finding would have to be about. Nothing is being withheld, and nothing is sitting in a laboratory awaiting publication.

The name is constructed exactly the way a genuine one would be, which is why it circulates so easily. GLP abbreviates glucagon-like peptide, the numbers following it run in sequence, and two of those numbers are already occupied. A third position therefore looks as though something ought to occupy it, preferably something newer and stronger than its predecessors. That expectation is what the name trades on, and it is where the reasoning collapses, because the numbering was never a succession of generations.

Which GLP peptides are named in the research?

human RCT

Two of them, and both are hormones the human intestine releases rather than medicines anybody designed. A 2009 trial tracking appetite hormones in people listed both of them within a single panel of blood readings, naming glucagon-like peptide-1 and glucagon-like peptide-2 next to each other.2 That is the family as practising scientists use it: two hormones, sampled from the same people on the same morning, doing entirely different jobs in the same gut.

GLP-1 is the famous member, and the medicines copied from it now fill a pharmacy shelf. A 2025 review names seven separate molecules as GLP-1 receptor agonists, which makes seven marketed products built on a single hormone.11 GLP-2 is the quiet member, with one approved imitation and a much narrower use. Between them they make up the whole family, and nothing among these sources attaches a hormone to the next number.

What is GLP-2, and what is it used for?

human case report

GLP-2, written out as glucagon-like peptide-2, is the second hormone in the family, and its work is on the intestinal wall rather than on appetite. The intestinal wall means the inner lining of the intestine, the thin layer of cells that absorbs nutrition and regenerates itself continuously. A review published in 2004 describes the hormone in those terms, as acting on the growth and the protection of that lining.1

An approved medication has been constructed on it. Teduglutide is an imitation of GLP-2, and a 2021 publication calls it the only one approved for long-term use in short bowel syndrome, a condition in which so much intestine has been removed that what remains cannot absorb enough food.5 Clinical trials of teduglutide produced approval from the Food and Drug Administration in 2012, for adults who would otherwise be fed through a vein.3

So the family does contain a second member, with a licence behind it. That member simply has nothing to do with body weight, which is part of why the vacant third position looks so inviting.

What does the number in a GLP name count?

review

It counts hormones, and it counts them in the order they were identified. GLP-1 and GLP-2 are two separate molecules existing alongside each other, which is exactly why the 2009 trial described above could measure both of them in the same participants on the same day. Neither arrived to supersede the other, and neither is a later edition of the other.

The medicines take their names from an entirely different system. GIP is another gut hormone, and its full name is glucose-dependent insulinotropic polypeptide. A 2025 review describes tirzepatide as a molecule targeting GIP receptors in addition to GLP-1, and describes retatrutide as acting at GLP-1, GIP and glucagon receptors together.11 Neither name carries a number, because neither molecule is a hormone awaiting one. They are imitations aimed at receptors, and the receptors are what gets listed.

A larger number within this family would therefore mean a different hormone, not a better medicine. The two counts measure different things, and nothing among these sources lines them up.

Why do searches pair GLP-3 with retatrutide?

human RCT

Because the assumption underlying that pairing is nearly correct. Retatrutide acts at three receptors at once instead of one, and a 2026 clinical trial calls it a GIP, GLP-1, and glucagon triple hormone receptor agonist.16 A 2023 trial of the identical molecule describes it as a single peptide with agonist activity at those three receptors.8 Three exceeds one, the GLP-1 medicines are the ones everybody has heard of, and so a three-receptor molecule gets filed as the next generation and awarded a bigger number.

Every step in that reasoning is defensible apart from the final one. The three in a triple agonist counts receptors, whereas the one in glucagon-like peptide-1 identifies a hormone, and those are different things to be counting. The arithmetic simply does not transfer from the one system to the other.

What these searches are reaching for is genuine, is named, and has been given to thousands of participants in trials. What the searches are calling it is a word that none of the papers behind this page uses. Our retatrutide hub carries the trials, the measurements and the regulatory position.

What is a triple agonist?

review

An agonist is a molecule that activates a receptor, roughly the way a key operates a lock. A triple agonist carries three of those keys on one chain, so a single weekly injection acts at three receptors rather than one. A 2025 review describes the approach as using single molecules to target several receptors at once.9

The same review sets out the ladder of combinations the field has assembled. There is a glucagon-like peptide-1 agonist by itself, a GLP-1 and GIP dual agonist such as tirzepatide, a GLP-1 and glucagon dual agonist, and finally a GLP-1, GIP and glucagon triple agonist at the summit.9

Consider what is really being counted in that progression. Every step incorporates another receptor, and not one of them appends a digit to the name of a hormone. The convention the field works by is to spell the receptors out, which is why three separate journals describe retatrutide by naming GIP, glucagon-like peptide-1 and glucagon in turn.

Is GLP-3 another name for retatrutide?

systematic review

Not in any sense a reader can depend upon, and the distinction matters. Retatrutide is one particular molecule carrying a code number, LY3437943, and a clinical record running into thousands of participants. A 2023 paper describes it as a medicine stimulating glucagon receptors in addition to the GLP-1 and GIP receptors.7 A 2026 meta-analysis of randomised trials calls it a novel triple receptor agonist in its own title.17

Attaching GLP-3 to that molecule does two unhelpful things at once. It manufactures a hormone that the research behind this page never names, and it conceals the three receptors that are the entire purpose of the design. Somebody handed a vial labelled GLP-3 has no way of telling which molecule is inside it.

If retatrutide is what you were after, the compound pages carry what the trials measured in participants, what was given, and what is still open.

Do the multi-receptor molecules have names of their own?

human RCT

They do, and there are more than most readers expect. A 2026 trial protocol describes survodutide as a glucagon receptor and glucagon-like peptide-1 receptor dual agonist.15 A 2025 analysis in participants with kidney disease describes cotadutide the same way, as a dual GLP-1 and glucagon receptor agonist.13 An earlier molecule, SAR425899, was administered to healthy volunteers and to patients with type 2 diabetes as an agonist at both of those receptors.4

On the three-receptor side, a 2025 review of development activity names retatrutide and efocipegtrutide together.12 A 2026 conference report introduces another, describing a phase 2 trial of DR10624 in patients with severely elevated blood fats.14

That is six molecules, and not a single one of them is numbered. The field labels these compounds by what they act upon, and when it wants a short name it invents another word. That is the convention a compound called GLP-3 would have to satisfy, and nothing among these sources positions it there.

Would a higher number mean a newer or stronger compound?

review

That is the assumption the name runs on, and the chronology alone dismantles it. A review published in 2004 already described what glucagon-like peptide-2 does, and the imitation built on it was licensed in 2012, which puts both ahead of several GLP-1 medicines on pharmacy shelves. The larger number did not indicate a later arrival.

Neither does it indicate a more powerful one, because GLP-2 is not aimed at the same target in the first place. A hormone acting on the lining of the intestine and a hormone acting on appetite cannot be ranked against each other. They are answering different questions entirely.

What really corresponds with the magnitude of an effect is the quantity of receptors. A 2025 review states that a GLP-1, GIP and glucagon triple agonist may offer superior weight loss efficacy over a GLP-1 agonist in obese adults.9 Observe the word may, and note that a review summarises other investigators' trials rather than running one. The field advances by adding receptors and testing them in people, and the hormone numbers sit outside that process altogether.

What is a GLP-3 dosage?

There is nothing to report, and that is the answer rather than an evasion. No source among the research behind this page provides a schedule, a quantity or a route of administration for a compound called GLP-3, because no source identifies such a compound at all. A schedule can only exist for a molecule that somebody has actually given to somebody.

What does exist is a set of published quantities for the real molecules, each attached to a named clinical trial, a named population and a measured outcome. Those figures belong to the compound they were tested on, and they do not travel across to a vial carrying a different name. A number extracted from a retatrutide trial and applied to something marketed as GLP-3 is a guess wearing a citation.

The retatrutide dosage page sets out what the trials administered, in what preparation and over how long, and it states plainly what those figures are and are not.

What are the side effects of something called GLP-3?

review

The question cannot be answered as asked, for exactly the reason just given. Side effects are counted in people who received a particular molecule, and a name with no molecule underneath it leaves nobody to count. That is a limit of the wording rather than a clean bill of health for anything.

For the compounds this name usually stands in for, the picture is documented and reasonably consistent. Obstipation, in the sentence that follows, means severe constipation. A 2025 review of this class reports that the adverse events are primarily gastrointestinal and include nausea, vomiting, obstipation, or diarrhea.10 A 2022 review puts the frequency of gut effects at 30% to 70% of patients receiving high-dose agonists and co-agonists.6

That is a class-level observation, and it is as far as this page travels. Which molecule did what, at which amount, in how many participants, and how many stopped, belongs on that compound's own safety page, and the retatrutide and GLP-1 safety pages carry it.

What is in a vial sold as GLP-3?

Nothing among the research behind this page has examined material marketed under that name, which is the plainest observation this page can offer about it. A label is a claim advanced by whoever is selling, and a label carrying a word the research behind this page does not use is a claim with nothing underneath it that anybody can verify.

The practical difficulty is that the word narrows nothing down. It could stand for retatrutide, for one of the two-receptor molecules, or for an ordinary GLP-1 medicine repackaged, and the label does not tell you which. A certificate of analysis naming GLP-3 is naming something no testing laboratory can hold a reference sample of.

Anybody buying in this category is far better served by a compound name they can enter into a trial register, which is what our buying pages ask for.

Will there be a GLP-3?

review

This page cannot answer that, and it should not pretend otherwise. What it can do is demonstrate what the development pipeline looks like from inside the literature, where new molecules appear carrying invented names rather than digits bolted onto a hormone.

A 2025 review surveying development activity lists a long-acting glucagon receptor agonist, four dual GLP-1 and glucagon agonists, and two triple agonists, identifying every one of them.12 Each entry is a molecule with its own word, its own code number and its own clinical programme, because that is how they are registered, financed and published.

So the question does have an answer, although not the answer its shape implies. The next arrival in this field will be a molecule, it will carry a name somebody invented for it, and whether that name contains a digit says nothing about what the molecule accomplishes.

Where does this leave someone who searched for GLP-3?

With a better question, which is worth considerably more than it appears. The wording was the wrong handle, but the thing underneath it is genuine, is documented and is in late-stage testing, and it has pages of its own.

If what you wanted was the three-receptor molecule, that is retatrutide, and the hub sets out what the trials measured and where the regulatory position stands. If what you wanted was the class that semaglutide belongs to, that is glucagon-like peptide-1, and the class page sets out which molecules are approved and how each is administered. If what you wanted was the hormone operating on the intestinal lining, that is glucagon-like peptide-2, and the medicine built on it is teduglutide.

Three questions, three genuine answers, and not one of them requires the designation GLP-3. Establishing the correct name is the cheapest precaution a reader can take before spending money on a vial.